December 10, 2020
Patients who receive red blood cell transfusions after TAVR fare worse in the first 30 days compared with others, results from the TRITAVI registry show.
In a propensity-matched analysis, transfusion was associated with about double the risk of early mortality (6.4% vs 3.1%), as well as greater risks of cerebrovascular accident and stage 2 or 3 acute kidney injury, according to researchers led by Marco Zimarino, MD, PhD (“SS. Annunziata” Hospital – Chieti, Italy).
Transfusion was independently associated with 30-day mortality on multivariable analysis, along with major vascular complications and major bleeding, they report in a study published recently online in
Circulation: Cardiovascular Interventions.
“Physicians should refrain from liberal transfusion to patients. They should refrain from using red blood cell transfusion as a fluid repletion means or to correct a lower-than-expected hemoglobin value,” Zimarino told TCMTD, adding that these result